Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (1-10 of 280) with videos related to

Pageof 28
Sort By:
The Lancet. Rheumatology|January 30, 2024
CRESS: improving the assessment of disease activity in Sjögren's syndromeDavid A Isenberg
Autoimmunity Reviews|February 22, 2012
Rituximab-it was the best of times, it was the worst of timesDavid A Isenberg
The Journal of Rheumatology|June 15, 2013
Dr. Eisenberg repliesDavid A Isenberg
Arthritis and Rheumatism|March 17, 2004
Systemic lupus erythematosus and Sjögren's syndrome: historical perspective and ongoing concernsDavid A Isenberg
The Journal of Rheumatology. Supplement|May 3, 2006
B cell targeted therapies in autoimmune diseasesDavid A Isenberg
The Journal of Rheumatology|January 3, 2013
Rhubarb and reliability -- a Jane Austen view of systemic lupus erythematosusDavid A Isenberg
Nature Clinical Practice. Rheumatology|August 26, 2006
The benefits and costs of biologic registersDavid A Isenberg
Arthritis Research & Therapy|April 13, 2012
Meryl Streep and the problems of clinical trialsDavid A Isenberg
Blood|September 8, 2020
How I treat anticoagulant-refractory thrombotic antiphospholipid syndromeHannah Cohen, David A Isenberg
Nature Reviews. Rheumatology|June 4, 2011
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphomaCatarina Dias, David A Isenberg
Pageof 28

Showing results (1-10 of 280) with videos related to

Sort By:
Pageof 28
The Lancet. Rheumatology|January 30, 2024
CRESS: improving the assessment of disease activity in Sjögren's syndromeDavid A Isenberg
Autoimmunity Reviews|February 22, 2012
Rituximab-it was the best of times, it was the worst of timesDavid A Isenberg
The Journal of Rheumatology|June 15, 2013
Dr. Eisenberg repliesDavid A Isenberg
Arthritis and Rheumatism|March 17, 2004
Systemic lupus erythematosus and Sjögren's syndrome: historical perspective and ongoing concernsDavid A Isenberg
The Journal of Rheumatology. Supplement|May 3, 2006
B cell targeted therapies in autoimmune diseasesDavid A Isenberg
The Journal of Rheumatology|January 3, 2013
Rhubarb and reliability -- a Jane Austen view of systemic lupus erythematosusDavid A Isenberg
Nature Clinical Practice. Rheumatology|August 26, 2006
The benefits and costs of biologic registersDavid A Isenberg
Arthritis Research & Therapy|April 13, 2012
Meryl Streep and the problems of clinical trialsDavid A Isenberg
Blood|September 8, 2020
How I treat anticoagulant-refractory thrombotic antiphospholipid syndromeHannah Cohen, David A Isenberg
Nature Reviews. Rheumatology|June 4, 2011
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphomaCatarina Dias, David A Isenberg
Pageof 28